{"nctId":"NCT01968967","briefTitle":"Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events","startDateStruct":{"date":"2013-10-29","type":"ACTUAL"},"conditions":["Hyperlipidemia"],"count":2139,"armGroups":[{"label":"Bococizumab (PF-04950615; RN316)","type":"EXPERIMENTAL","interventionNames":["Drug: Bococizumab (PF-04950615; RN316)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"Bococizumab (PF-04950615; RN316)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Treated with a statin.\n* Fasting LDL-C \\> 70 mg/dL and triglyceride \\<=400 mg/dL.\n* High or very high risk of incurring a cardiovascular event.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding females.\n* Cardiovascular or cerebrovascular event of procedures during the past 30 days.\n* Congestive heart failure NYHA class IV.\n* Poorly controlled hypertension.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"22.55"},{"groupId":"OG001","value":"-54.9","spread":"26.84"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Total Cholesterol (TC) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"16.18"},{"groupId":"OG001","value":"-34.9","spread":"18.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"18.68"},{"groupId":"OG001","value":"-30.5","spread":"21.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"18.75"},{"groupId":"OG001","value":"-25.3","spread":"23.43"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"18.83"},{"groupId":"OG001","value":"-50.4","spread":"27.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"21.43"},{"groupId":"OG001","value":"-44.9","spread":"31.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"21.78"},{"groupId":"OG001","value":"-37.4","spread":"32.92"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"21.22"},{"groupId":"OG001","value":"-49.7","spread":"25.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"24.65"},{"groupId":"OG001","value":"-43.8","spread":"30.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"24.62"},{"groupId":"OG001","value":"-36.8","spread":"32.73"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides (TG) Cut-off of Less Than (<) 200 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"23.07"},{"groupId":"OG001","value":"-55.6","spread":"26.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"27.17"},{"groupId":"OG001","value":"-49.2","spread":"32.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"26.65"},{"groupId":"OG001","value":"-40.6","spread":"36.45"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (>=) 200 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"20.82"},{"groupId":"OG001","value":"-53.0","spread":"26.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"28.21"},{"groupId":"OG001","value":"-42.8","spread":"31.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"27.78"},{"groupId":"OG001","value":"-36.3","spread":"34.88"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Lipoprotein (a) (Lp[a]) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"85.08"},{"groupId":"OG001","value":"-26.3","spread":"42.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":"146.00"},{"groupId":"OG001","value":"-22.7","spread":"51.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"139.49"},{"groupId":"OG001","value":"-20.9","spread":"110.14"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"13.92"},{"groupId":"OG001","value":"6.2","spread":"14.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"15.25"},{"groupId":"OG001","value":"6.1","spread":"15.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"16.09"},{"groupId":"OG001","value":"6.5","spread":"17.87"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 24, 52: Treatment Period","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"27.45"},{"groupId":"OG001","value":"-47.5","spread":"32.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"27.00"},{"groupId":"OG001","value":"-39.5","spread":"36.08"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"38.25"},{"groupId":"OG001","value":"-12.9","spread":"39.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"51.06"},{"groupId":"OG001","value":"-11.5","spread":"41.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"43.63"},{"groupId":"OG001","value":"-12.5","spread":"40.82"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"11.22"},{"groupId":"OG001","value":"2.8","spread":"11.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"12.10"},{"groupId":"OG001","value":"2.7","spread":"11.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"12.34"},{"groupId":"OG001","value":"2.6","spread":"13.75"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Apolipoprotein A-II (ApoA-II) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"13.05"},{"groupId":"OG001","value":"-1.0","spread":"13.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"13.56"},{"groupId":"OG001","value":"0.1","spread":"14.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"13.50"},{"groupId":"OG001","value":"-1.0","spread":"13.72"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"38.25"},{"groupId":"OG001","value":"-12.9","spread":"39.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"51.06"},{"groupId":"OG001","value":"-11.5","spread":"41.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"43.63"},{"groupId":"OG001","value":"-12.5","spread":"40.82"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Less Than (<) 200 Milligram Per Deciliter (mg/dL) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"109.1","spread":"33.24"},{"groupId":"OG001","value":"107.1","spread":"30.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"25.70"},{"groupId":"OG001","value":"-59.3","spread":"32.30"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) by Triglycerides Cut-off of Greater Than or Equal to (>=) 200 Milligram Per Deciliter (mg/dL) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125.9","spread":"40.08"},{"groupId":"OG001","value":"121.5","spread":"37.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"29.08"},{"groupId":"OG001","value":"-64.8","spread":"38.94"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113.5","spread":"35.90"},{"groupId":"OG001","value":"110.9","spread":"33.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"26.66"},{"groupId":"OG001","value":"-60.7","spread":"34.22"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Total Cholesterol (TC) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"186.3","spread":"40.77"},{"groupId":"OG001","value":"183.1","spread":"38.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"31.62"},{"groupId":"OG001","value":"-64.5","spread":"38.01"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Non High Density Lipoprotein Cholesterol (HDL-C) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"138.0","spread":"39.67"},{"groupId":"OG001","value":"135.3","spread":"36.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"30.93"},{"groupId":"OG001","value":"-67.0","spread":"38.89"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Apolipoprotein B (ApoB) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":"24.26"},{"groupId":"OG001","value":"92.3","spread":"22.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"18.35"},{"groupId":"OG001","value":"-46.0","spread":"26.58"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting Lipoprotein (a) (Lp[a]) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":"49.77"},{"groupId":"OG001","value":"46.4","spread":"55.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"12.07"},{"groupId":"OG001","value":"-10.6","spread":"18.36"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Fasting High Density Lipoprotein Cholesterol (HDL-C) at Week 12","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3","spread":"12.42"},{"groupId":"OG001","value":"47.8","spread":"12.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"6.84"},{"groupId":"OG001","value":"2.5","spread":"7.07"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Ratio of Fasting Total Cholesterol (TC) to High Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"1.22"},{"groupId":"OG001","value":"4.0","spread":"1.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.86"},{"groupId":"OG001","value":"-1.5","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.96"},{"groupId":"OG001","value":"-1.4","spread":"1.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.97"},{"groupId":"OG001","value":"-1.1","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Ratio of Fasting Apolipoprotein B (ApoB) to Apolipoprotein A-I (ApoA-I) at Week 12, 24 and 52","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.21"},{"groupId":"OG001","value":"0.7","spread":"0.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.14"},{"groupId":"OG001","value":"-0.3","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.15"},{"groupId":"OG001","value":"-0.3","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.16"},{"groupId":"OG001","value":"-0.2","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (<=) 100 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.3","spread":null},{"groupId":"OG001","value":"90.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":null},{"groupId":"OG001","value":"85.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.0","spread":null},{"groupId":"OG001","value":"79.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Fasting Low Density Lipoprotein Cholesterol (LDL-C) Less Than or Equal to (<=) 70 Milligram Per Deciliter (mg/dL) at Week 12, 24 and 52","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"78.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"69.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"61.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of PF-04950615 at Week 12, 24 and 52","description":"Plasma concentration of PF-04950615 at Week 12, 24 and 52 was reported.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.91","spread":"4.987"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.74","spread":"5.772"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":"4.685"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs) Related to Type 1 or 3 Hypersensitivity Reactions and Injection Site Reactions","description":"Type 1 hypersensitivity or allergic reactions were possible in response to any injected protein and included shortness of breath, urticaria, anaphylaxis and angioedema. Type 3 hypersensitivity reactions were similar to Type 1 hypersensitivity reactions but were likely to be delayed from the time of injection and included symptoms such as rash, urticaria, polyarthritis, myalgia's, polysynovitis, fever and if severe then included glomerulonephritis. Injection site reactions included injection site bruising, discolouration, erythema, haematoma, haemorrhage, nodule, induration, inflammation, mass, pain, paraesthesia, pruritus, swelling, vesicles, warmth, scab and rash. Participants with type 1 or type 3 hypersensitivity reactions and participants with injection site reactions were reported in this outcome measure.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"144","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb): Treatment Period","description":"Percentage of participants with at least 1 positive ADA titer or 1 positive nAb titer were reported. ADA titer \\>=6.23 (log2) unit was considered to be ADA positive and nAb titer \\>=1.58 (log2) unit was considered to be nAb positive.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"46.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"30.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Changed Concomitant Medication During Extension Period","description":"In this outcome measure, total number of participants who changed their lipid-lowering medications or added a monoclonal antibody medication during the extension period were reported.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 58 Follow-up Visit, 71, 84, 97 and 110: Extension Period","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"24.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.4","spread":"41.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.8","spread":"25.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.8","spread":"31.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":"28.65"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibodies (nAb): Extension Period","description":"Percentage of participants with at least 1 positive ADA titer or 1 positive nAb titer were reported. ADA titer \\>=6.23 (log2) unit was considered to be ADA positive and nAb titer \\>=1.58 (log2) unit was considered to be nAb positive.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":150,"n":1065},"commonTop":["Injection site reaction","Upper respiratory tract infection","Hypertension"]}}}